Interviews

Gary Lyman, MD, MPH, an oncologist and hematologist, discusses how biosimilars have fared in the oncology space compared to other therapeutic areas.

Patients with a cough lasting more than 8 weeks are diagnosed with chronic cough, and for a subpopulation of those patients there is no treatable underlying cause of their cough, said Peter Dicpinigaitis, MD, professor of medicine at the Albert Einstein College of Medicine and director of the Montefiore Cough Center.

Ivo Abraham, PhD, RN, a professor with the University of Arizona Health Sciences in the Department of Pharmacy Practice, discusses how the COVID-19 pandemic is likely to impact oncology biosimilar utilization.

Robert A. Gabbay, MD, PhD, the chief science and medical officer at the American Diabetes Association (ADA), outlines why updates were made to the ADA’s Living Standards of Care.

Pediatric patients with atopic dermatitis (AD) often vary in disease severity and it can be difficult to assess how much of a topical therapy is needed, said Lawrence F. Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children's Hospital-San Diego.

Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital Heart & Vascular Center and professor of medicine at Harvard Medical School, outlines the benefits of sotagliflozin for individuals with type 2 diabetes and chronic kidney disease or heart failure.

Camillo Ricordi, MD, FNAI, describes the process of islet transplantation and how it can benefit individuals with type 1 diabetes.

Patients with a chronic cough that persists even after treatment usually see a few specialists and have lingering triggers that cause their cough, explained Laurie Slovarp, PhD, CCC-SLP, associate professor in the School of Speech, Language, Hearing, and Occupational Sciences at University of Montana.

The Supreme Court recently upheld the Affordable Care Act, under which HIV and AIDS are considered preexisting conditions, by a vote of 7 to 2.

Catlin Dennis, MPH, describes her research on the impacts of COVID-19 on Oregon’s most medically and socially vulnerable youth with diabetes.

Leslie Eiland, MD, discusses the benefits of remote monitoring among patients with type 1 diabetes (T1D) living in rural America.

Bobeck Modjtahedi, MD, describes how Kaiser Permanente leveraged its telehealth resources to provide care to those with diabetic retinopathy (DR) throughout the COVID-19 pandemic.

Michelle Litchman, PHD, FNP-BC, FAANP, FADCES, an assistant professor at the College of Nursing at the University of Utah, highlights her research on the benefits of concurrent continuous glucose monitoring and online peer support groups for Spanish-speaking patients with diabetes.

Aleksandar Kostic, PhD, an assistant professor of microbiology at Harvard Medical School, describes the research linking gut microbiota and incidence of type 1 diabetes.

Ezio Bonifacio, PhD, discusses the optimal time to begin monitoring for type 1 diabetes (T1D) in children genetically at risk for the disease.

Ann Goebel-Fabbri, PhD, a clinical psychologist in Boston, Massachusettes, outlines trends in eating disorders among patients with type 1 diabetes.

Mary Pat Gallagher, MD, of NYU Langone Health, explains her research documenting new onset diabetes and diabetic ketoacidosis (DKA) throughout the COVID-19 pandemic.

David McIntyre, MD, FRACP, gives an overview of his talk "Diagnosis and Management of Diabetes in Pregnancy During the COVID-19 Pandemic," to be presented at the American Diabetes Association's (ADA) 81st Scientific Sessions.

Ivo Abraham, PhD, RN, a professor with the University of Arizona Health Sciences in the Department of Pharmacy Practice, talks about the role that the pandemic has played in the struggle between biosimilar pegfilgrastims and the on-body injector version of the reference product.

Robert A. Gabbay, MD, PhD, the chief science and medical officer at the American Diabetes Association (ADA) offers insights on trial results and sessions to be presented at this year's ADA Scientific Sessions, taking place virtually June 25-29, 2021.

Robert A. Gabbay, MD, PhD, the chief science and medical officer at the American Diabetes Association (ADA), previews sessions to be presented at the ADA's 81st Scientific Sessions.

Michael D. Anestis, PhD, executive director of the New Jersey Gun Violence Research Center and associate professor at the Rutgers School of Public Health, discusses his research on firearm ownership and suicide, in addition to steps needed to help decrease rates of gun-inflicted suicide and gun violence in general.

Stephanie Lovinsky-Desir, MD, MS, discusses the need for concrete changes addressing social determinants of health (SDOH) and respiratory health.

Ivo Abraham, PhD, RN, a professor in the Department of Pharmacy Practice at University of Arizona Health Sciences, talks about the results from his cost-efficiency studies and how Amgen’s Onpro pegfilgrastim device has affected cancer care and costs.

Michael Thorpy, MD, director, Sleep-Wake Disorders Center, Montefiore Medical Center, and professor of neurology, Albert Einstein College of Medicine, speaks on the efficacy of solriamfetol observed in patients with excessive daytime sleepiness associated with narcolepsy, and which patient groups may best benefit from this therapy.

Fernando Holguin, MD, explains why increased risk of pulmonary disease may be overlooked when assessing obesity risk factors.

Anne Marie Morse, DO, pediatric neurologist and sleep medicine specialist, Geisinger, discusses factors contributing to insufficient screening of obstructive sleep apnea (OSA) in patients with stroke and how a team-based approach fared in expediting diagnosis.

Ibrutinib is currently a standard of care in relapsed/refractory chronic lymphocytic leukemia, but zanubrutinib is an effective second-line and second-generation option, said Peter Hillmen, PhD, MB ChB, professor at the University of Leeds.

Rajasi Mills, MS, vice president, SleepIQ Health, Sleep Number, speaks on the practical use of Sleep Number 360 smart beds in measuring sleep metrics and leveraging data to identify symptoms characteristic of COVID-19 and other respiratory illnesses.

OTC cough medicines may have some temporary benefit, but they don't penetrate the nerves in the airways, which are believed to be the mechanism behind refractory chronic cough, says Jacky Smith, MB, ChB, FRCP, PhD, professor of respiratory medicine at the University of Manchester and an honorary consultant at Manchester University NHS Foundation Trust.